Company Overview

BioCardia, Inc. is a U.S.-based biotechnology and regenerative medicine company focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. The company operates primarily within the biopharmaceutical, medical device, and regenerative medicine industries, with a strategic emphasis on therapies intended to repair damaged tissue and improve functional outcomes in patients with chronic heart failure and ischemic cardiovascular conditions. BioCardia combines therapeutic biologics with proprietary delivery technologies designed to improve the precision and effectiveness of cell-based treatments.

The company’s principal revenue drivers historically have included clinical-stage therapeutic development, licensing arrangements, and sales or partnerships associated with its proprietary delivery catheter platforms. BioCardia is particularly known for its lead therapeutic candidates targeting heart failure and myocardial ischemia, including programs based on autologous and allogeneic cell therapies. Its strategic positioning is supported by an integrated platform that combines biologic therapeutics with minimally invasive delivery systems, differentiating the company from developers focused solely on drug or device technologies. Founded in 2002 and headquartered in California, BioCardia evolved from a cardiovascular device-focused business into a regenerative medicine company centered on advanced cellular therapeutics and translational clinical development.

Business Operations

BioCardia conducts operations through a combination of therapeutic development activities and interventional cardiovascular device technologies. Its primary business areas include the CardiAMP Cell Therapy System, the CardiALLO Cell Therapy platform, and proprietary catheter-based delivery systems such as the Helix Biotherapeutic Delivery System and related navigation technologies. The company generates revenue primarily from collaborative agreements, device-related activities, and limited commercial or licensing arrangements while advancing multiple clinical-stage therapeutic programs.

The company’s operations are concentrated in the United States, though its clinical and strategic activities have involved international investigators, institutions, and regulatory interactions. BioCardia controls intellectual property related to cell processing methodologies and intramyocardial delivery technologies designed for minimally invasive administration of biologic therapies. The company has also maintained relationships with academic institutions, clinical research organizations, and manufacturing partners supporting clinical development and regulatory execution. Public filings indicate that BioCardia’s operational strategy relies heavily on advancing clinical trials, securing regulatory approvals, and establishing partnerships capable of supporting commercialization and broader market adoption.

Strategic Position & Investments

BioCardia’s strategic direction centers on regenerative therapies for cardiovascular disease, particularly heart failure with reduced ejection fraction and ischemic cardiac conditions. Its growth initiatives have focused on advancing late-stage clinical programs, expanding clinical evidence for its therapeutic platforms, and leveraging its delivery technology portfolio to support both internal and partnered therapeutic applications. The company has emphasized obtaining regulatory milestones and generating clinical data intended to differentiate its therapies in a highly competitive cardiovascular treatment market.

The company’s most significant investments have involved development of the CardiAMP and CardiALLO therapeutic programs, alongside continued refinement of catheter-based biologic delivery systems. BioCardia has also explored broader applications of its delivery technologies in structural heart and biologic intervention markets. Public disclosures indicate participation in emerging regenerative medicine sectors involving autologous bone marrow therapies, allogeneic cellular platforms, and biologic delivery optimization. While BioCardia remains a relatively small-cap clinical-stage company, its strategic positioning reflects an effort to combine device engineering expertise with cell therapy development to create integrated treatment platforms.

Geographic Footprint

BioCardia is headquartered in Sunnyvale, California, and its principal operational activities are centered in the United States. The company’s clinical development programs have involved collaborations with medical centers and investigators across multiple U.S. regions, particularly within advanced cardiovascular care networks and academic research institutions. Its regulatory and commercial focus has historically prioritized the U.S. market due to the scale of cardiovascular disease treatment demand and the importance of FDA clinical pathways for regenerative medicine products.

Internationally, BioCardia has maintained selective engagement through clinical research collaborations, intellectual property activities, and strategic interactions in regions including Europe and parts of Asia-Pacific. Although the company does not currently operate as a large multinational commercial enterprise, its technologies and therapeutic platforms have relevance to global cardiovascular treatment markets. Publicly available information indicates that international expansion opportunities remain tied primarily to future regulatory approvals, commercialization partnerships, and multicenter clinical adoption.

Leadership & Governance

BioCardia was founded by Peter Altman, who has played a central role in shaping the company’s strategy in regenerative cardiovascular medicine and interventional therapeutic delivery technologies. Leadership has consistently emphasized clinical validation, minimally invasive biologic delivery, and development of therapies addressing unmet needs in heart failure and ischemic disease. The company operates under a governance structure typical of publicly traded biotechnology companies, with executive oversight focused on clinical development, regulatory strategy, financing, and commercialization planning.

Key executives and leadership figures include:

• Peter Altman – President and Chief Executive Officer
• Timothy McCarthy – Chief Financial Officer
• Andrew Turnbull – Chief Business Officer
• Michael Aragon – Vice President of Clinical and Regulatory Affairs

The company’s leadership philosophy has emphasized integrating therapeutic biologics with proprietary delivery systems to improve patient outcomes while pursuing evidence-driven regulatory and commercialization strategies. Public company filings and investor communications consistently reflect a focus on disciplined clinical execution, strategic partnerships, and long-term value creation through regenerative medicine innovation.